Skip to content
Screener

CRISPR Therapeutics CRSP Q1 2026 earnings

Reported May 4, 2026 · Before market open

Revenue$1.5MMiss by $4.6M
EPS-$1.28Miss by $0.08
Revenue estimate$6.1M
EPS estimate-$1.20

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$14.8M
EPS estimate-$1.06

Financials

Q1 2026

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$4.57B+56.4%
Enterprise value$4.93B+69.8%
P/S1,112.8×+1,035×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Segments

By product

See full
Collaboration Revenue$1.0M—
Grant$458.0K-47.1%

FAQ

When did CRISPR Therapeutics report Q1 2026 earnings?
CRISPR Therapeutics (CRSP) reported Q1 2026 earnings on May 4, 2026 before market open.
What were CRISPR Therapeutics's Q1 2026 revenue and EPS?
CRISPR Therapeutics reported revenue of $1.5M and eps of $-1.28 for Q1 2026.
Did CRISPR Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $6.1M by $4.6M. EPS missed the consensus estimate of $-1.20 by $0.08.
How did CRISPR Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 68.6% from $865.0K a year earlier and eps grew 19.0% from $-1.58.
Where can I find CRISPR Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-204147) and the 10-Q periodic report (0001193125-26-204188) directly on SEC EDGAR. The filing index links above go to sec.gov.